AzTrials
AzTrials

Hip OsteoarthritisNCT07104279

Z1 Hip System: Post-Market Clinical Follow Up Study

An observational study of Hip Osteoarthritis and Acute Traumatic Fracture of the Femoral Head or Neck, run by Zimmer Biomet at 5 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The objectives of this study are to confirm the early to mid- term safety, performance, and clinical benefits of the Z1 Femoral Hip System in hemi- and primary total hip arthroplasty. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Z1 Femoral Hip System
Type of treatment
Medical device
How many people
300 participants
Where
5 sitesUnited States
Study dates
13 Oct 2025to Aug 2031
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population should consist of up to 300 subjects implanted with the Z1 Femoral Hip System in hemi or total hip arthroplasty, according to the approved indications. Inclusion and exclusion criteria are based on the indications and contraindications defined in the IFU for the Z1 Femoral Hip System.

Who may be able to join

  • Patient is at least 18 years old and skeletally mature
  • Patient is physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol, including all scheduled study evaluations
  • Patient, or the patient's legally authorized representative, is willing and able to participate in the Informed Consent process and provide their consent
  • Independent of study participation, patient is a candidate and qualifies for primary total hip or hemi-arthroplasty based on physical exam and medical history including at least one of the following:
  • Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases
  • Acute traumatic fracture of the femoral head or neck
  • Avascular necrosis (AVN) of the femoral head

Who cannot join

  • Revision arthroplasty
  • Acute, chronic, local, or systemic infection(s)
  • Severe muscular, neural, or vascular diseases that endanger the limb(s) involved
  • Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible
  • Total or partial absence of the muscular or ligamentous apparatus
  • Any concomitant diseases that can jeopardize the functioning and the success of the implant
Show all 14Show fewer
  • Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel, etc.)
  • Local bone tumors and/or cysts
  • Patient has any condition that would, in the Investigator's opinion, place the patient at undue risk or interfere with the study
  • Any vulnerable subject:
  • a prisoner
  • a patient known to be pregnant
  • mentally incompetent or unable to understand what participation in the study entails
  • a known substance abuser

Trial locations and contacts

5 sites in 1 country. Contact the study team or a site near you to ask about taking part.

5 sites in 1 country

United States5 sites, 5 recruiting
  • Anderson Orthopaedic/Anderson Orthopaedic Research Institute

    Alexandria, Virginia, 22308

    Robert Hopper, 571-345-5877, rhopper@aori.org

    Robert Sershon, MD

    Recruiting
  • OrthoCarolina/OrthoCarolina Research Institute

    Charlotte, North Carolina, 28207

    Alexis Ready, 704-323-3620, alexis.ready@orthocarolina.com

    Caleb Michalek, 704.323.3698, caleb.michalek@orthocarolina.com

    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Laura Stiegel, 216-442-5511, STIEGEL@ccf.org

    Matthew Deren, MD

    Recruiting
  • Mokan Orthopedic Research and Consulting

    Platte City, Missouri, 64079

    Mandi Peterson, 816-674-1229, mandi@petersonhipandknee.com

    Blake Peterson, MD

    Recruiting
  • Orthopedic & Fracture Specialists

    Portland, Oregon, 97225

    Jacquline Shelton, 503-214-5209, jacquline.shelton@OandFS.com

    Elizabeth Lieberman, MD

    Recruiting

Other trials in United States

About this study

Official title: Multicenter, Post-Market Clinical Follow-up Study of the Z1 Femoral Hip System

The objectives of this study are to confirm the early to mid- term safety, performance, and clinical benefits of the Z1 Femoral Hip System in hemi- and primary total hip arthroplasty.

Cohort 0 The primary endpoint is defined by the survival of the implant system at 2 years, which is based on the absence of removal of the study device and will be evaluated using a one-sample proportion as well as using the Kaplan Meier method. The safety of the system will additionally be assessed by monitoring the frequency and incidence of adverse events, including relation to implant, instrumentation, and/or procedure.

Read more

The secondary endpoints are defined by the functional performance and clinical benefits of the study device and are assessed by patient-reported clinical outcomes measures (PROMs)(Hip dysfunction and Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)).

Cohort 1 The primary performance endpoint is the assessment of the HOOS JR, specifically the within-patient change from baseline to 2-years post-op. The mean change from baseline will be compared against a minimal clinically important difference (MCID) of 9.46 points.

The key secondary safety endpoint is defined by the survival of the implant system at 2 years, which is based on the absence of removal of the study device and will be evaluated using a one-sample proportion as well as using the Kaplan Meier method. The safety of the system will additionally be assessed by monitoring the frequency and incidence of adverse events, including relation to implant, instrumentation, and/or procedure.

Exploratory outcomes include:

  • EuroQol 5 Dimensions (EQ-5D)
  • Patient Satisfaction
  • Radiographic outcomes, where available
Read the detailed description

Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relief pain and debilitating symptoms. A femoral stem component is used in conjunction with a femoral head component for the replacement of the proximal femur in total hip or hemi hip arthroplasty. THA now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications include osteoarthritis, rheumatoid arthritis, avascular necrosis (AVN) and hip fractures. The surgical procedure consists in replacing the head of the femur and acetabulum (socket) with a prosthesis. Another type of hip arthroplasty is called Hemi arthroplasty, which does not include the replacement of the acetabulum.

This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum. Device components are made from durable materials that can withstand loads applied to the artificial hip joint during physical activity, are resistant to corrosion and fatigue, provide minimal friction and wear, and are biocompatible. Commonly used materials include cobalt chrome, commercially pure titanium, titanium alloy with aluminum and vanadium, ceramics, and ultrahigh molecular weight polyethylene.

Clinical studies have proven implant longevity in both cementless and cemented THA, offering patients effective long-term relief. In cementless THA, successful biological fixation is dependent on bony on-growth onto the surface of the prosthesis whereas, cemented fixation depends on a stable interface between prosthesis and cement and a solid mechanical bond between cement and bone. Ultimately, the goal of a THA is to bring the patients back to their normal routine without pain and stiffness. THA and hemiarthroplasty are both very successful procedures with an 84-97% patient satisfaction rate and an implant survival of over 90% after 10 years (THA) and implant survival of approximately 93% at 10 years (Hemiarthroplasty).

The Z1 Femoral Hip System consists of femoral hip stems intended for use in total or hemi hip arthroplasty. The triple-tapered stem is designed for implantation into the proximal femur and mates with compatible femoral heads and adapters for use in total or hemi hip arthroplasty through a 12/14 male taper connection.

The stems are manufactured from a forged titanium alloy Ti-6Al-4V and have a wedge-shaped design, with a proximal-to-distal taper. Apart from the highly polished femoral neck region, the entire surface of the stem is gritblasted and sprayed with a Ti-6Al-4V titanium alloy plasma coating followed by a hydroxyapatite (HA) overcoat. Offered in multiple sizes and neck lengths, the stems are available in Standard, High Offset, and Coxa Vara offsets to accommodate various patient anatomies. The hip stems are provided sterile and are for single use only. System-specific instrumentation is available to prepare the femur for implantation of the Z1 Hip System femoral stems. The Z1 Hip System is for use only with the Zimmer Biomet femoral heads and adapters, bipolar heads, and acetabular shells and liners identified in the package insert as compatible components.

Being tested
Z1 Femoral Hip System
Keywords
total hip arthroplasty, total hip replacement, osteoarthritis, hemiarthroplasty, partial hip replacement
Medical subject headings
Osteoarthritis, Hip, Femur Head Necrosis, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Z1 Femoral Hip SystemDevice

    Subjects who will be implanted with the Z1 Femoral Hip System in hemi-hip arthroplasty and primary total hip arthroplasty

Study groups in NCT07104279
Study groupRoleWhat they receive
Cohort 0Subjects implanted with the Z1 Femoral Hip System manufactured by Zimmer, Inc.: AristoTech (Luckenwalde, Germany)
Receives: Device: Z1 Femoral Hip System
Cohort 1Subjects implanted with the Z1 Femoral Hip System manufactured by Zimmer, Inc. (Warsaw, IN, USA)
Receives: Device: Z1 Femoral Hip System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 2 Year Primary Outcome (Cohort 0)

    The primary endpoint is defined by the survival of the implant system at 2 years, which is based on the absence of removal of the study device and will be evaluated using a one-sample proportion as well as using the Kaplan Meier method. The safety of the system will additionally be assessed by monitoring the frequency and incidence of adverse events, including relation to implant, instrumentation, and/or procedure.

    Cohort 1

    Measured: 2 years post-operative

  2. 2 Year Primary Outcome (Cohort 1)

    The primary performance endpoint is the assessment of the HOOS JR, specifically the within-patient change from baseline to 2-years post-op. The mean change from baseline will be compared against a minimal clinically important difference (MCID) of 9.46 points.

    Measured: 2 years post-operative

Secondary outcomes (2)
  1. HOOS Jr

    Cohort 0:

    The functional performance and clinical benefits of the study device will be assessed by a patient-reported clinical outcomes measure (PROM)(HOOS JR).

    Measured: 5 years post-operative

  2. Survivorship

    Cohort 1:

    The key secondary safety endpoint is defined by the survival of the implant system at 2 years, which is based on the absence of removal of the study device and will be evaluated using a one-sample proportion as well as using the Kaplan Meier method. The safety of the system will additionally be assessed by monitoring the frequency and incidence of adverse events, including relation to implant, instrumentation, and/or procedure. Each secondary endpoint will be followed out to 5 years.

    Measured: 2 Years post-operative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2025
  2. Study start13 Oct 2025
  3. Primary completionAug 2028 (estimated)
  4. Study completionAug 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07104279
Sponsor's protocol ID
CMU2024-25H
Status last verified
Oct 2026
First submitted
29 Jul 2025
Last updated
16 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in